Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International (BAX) surged 19% this week after second-quarter earnings crushed expectations. The medical device and pharmaceutical company posted $2.96 billion in sales, up 5% year-over-year, and lifted full-year guidance across the board.

The company now expects revenue growth of 3-4% for the full year and adjusted earnings per share between $1.95 and $2.15. Management attributed the beat to strength in both product categories and across all geographic regions, signaling broad-based momentum rather than reliance on a single segment.

The 19% weekly gain marks one of the sharper moves for BAX in recent quarters, with the revised guidance providing a clear catalyst for the rally. The raised EPS range gives the stock a concrete valuation anchor heading into the second half of the year.